Pluristem Therapeutics to Present at the German Equity Forum
NEW YORK, Mar 31, 2009 (BUSINESS WIRE) -- Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today that Zami Aberman, Chairman, President and CEO, has been invited by the Equity Forum in Stuttgart, Germany to present updates on the Company's corporate development in Germany and its Phase I clinical trials using the Company's placental-derived stem cell product, PLX-PAD. Mr. Aberman will also discuss the arrangements with Charite - Universitatsmedizin Berlin and Franziskus-Krankenhaus Hospital for the upcoming Critical Limb Ischemia (CLI) clinical trials in Germany. The presentation, which is organized by the Deutsche Borse and the KfW SME Bank, will be held on April 29, 2009.
"Pluristem has established long term scientific collaborations with outstanding German institutions such as the Charite - Universitatsmedizin Berlin and the Fraunhofer Institute for Immunology and Cell Therapy in Liepzig," stated Zami Aberman, Chairman, President and CEO of Pluristem. "We look forward to presenting our clinical trial's progress, as well as the Company's future business plans, to the investment community at the Stuttgart Equity Forum."
About the German Equity Forum
The German Equity Forum is one of the largest capital market conferences in Europe. The conference is organized by the Deutsche Borse and the KfW SME Bankengruppe. The Deutsche Borse is one of the world's leading exchange organizations, which provides investors, financial institutions and companies access to global capital markets, while KfW Bankengruppe gives impetus to economic, social and ecological development worldwide and is a promotional bank under the ownership of the Federal Republic and the Lander (federal states).
About Pluristem
Pluristem Therapeutics Inc. is a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from human placenta, a non-controversial, non-embryonic, adult stem cell source.
These placental adherent stromal cells (ASCs) are expanded in the Company's proprietary PluriX(TM) 3D bioreactor, which imitates the natural 3D microenvironment of these cells and does not require supplemental growth factors or other exogenous materials. Pluristem believes that the resultant PLX (PLacental eXpanded) cells' efficacy may be related to the secretion of cytokines or other potent immune modulators. Furthermore, PLX cells are immune privileged and possess immunomodulatory properties, thus protecting the recipient from immunological reactions that often accompany transplantations.
Pluristem's first product in development, PLX-PAD, is intended to improve the quality of life of millions of people suffering from peripheral artery disease (PAD). The Company's products in development also include PLX-IBD, targeting Inflammatory Bowel Disease (IBD); PLX-MS, targeting Multiple Sclerosis; PLX-BMT, targeting the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood; and PLX-STROKE, targeting ischemic stroke.
Pluristem has offices in the USA with research and manufacturing facilities in Israel.
See our product animation on YouTube: Animation |
